Senti Biosciences Holdings, Inc. (SNTI) stock
SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.09−0.01 (-10.31%)
Close on Nov 18, 2026Market cap $2.71MP/E –Yield –
Senti Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Senti Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$38.05M. For fiscal 2025 it was -$43.44M. The highest annual figure on record is -$34.64M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$43.44M | – |
| FY2024 | Dec 31, 2024 | -$41.40M | – |
| FY2023 | Dec 31, 2023 | -$52.40M | – |
| FY2022 | Dec 31, 2022 | -$34.90M | – |
| FY2021 | Dec 31, 2021 | -$34.64M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$14.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.48M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.45M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.05M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.50M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.87M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.35M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.04M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.38M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.68M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.01M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.14M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.70M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.06M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.97M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.81M | – |
See a number that looks wrong?